Collaborations & Alliances

Skyhawk, Genentech Enter Exclusive Multi-target RNA Alliance

Will leverage SkySTAR platform to discover and develop small molecule treatments for oncology and neurological disease targets

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Skyhawk Therapeutics, Inc. has entered into a multi-target exclusive option and license agreement with Genentech, a member of the Roche Group, to develop and commercialize small molecules that modulate RNA splicing. Skyhawk will use its SkySTAR technology platform to discover and develop innovative small molecule treatments directed to certain oncology and neurological disease targets. The agreement grants Genentech an exclusive worldwide license to develop and commercialize potential therape...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters